Wall Street is positive on Biora Therapeutics Inc (PROG). On average, analysts give Biora Therapeutics Inc a Buy rating. The average price target is $2.666, which means analysts expect the stock to climb by 210.00% over the next twelve months. That average ranking earns Biora Therapeutics Inc an Analyst Rating of 21, which is better than 21% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating PROG a Buy today. Find out what this means to you and get the rest of the rankings on PROG!